APA

Vogl U. M., Andalibi H., Klaus A., Vormittag L., Schima W., Heinrich B., Kafka A., Winkler T. & Öhler L. (20190415). Nab-paclitaxel and gemcitabine or FOLFIRINOX as first-line treatment in patients with unresectable adenocarcinoma of the pancreas: does sequence matter?. : BMC cancer.

Chicago

Vogl Ursula M, Andalibi Haleh, Klaus Alexander, Vormittag Laurenz, Schima Wolfgang, Heinrich Bettina, Kafka Alice, Winkler Thomas and Öhler Leopold. 20190415. Nab-paclitaxel and gemcitabine or FOLFIRINOX as first-line treatment in patients with unresectable adenocarcinoma of the pancreas: does sequence matter?. : BMC cancer.

Harvard

Vogl U. M., Andalibi H., Klaus A., Vormittag L., Schima W., Heinrich B., Kafka A., Winkler T. and Öhler L. (20190415). Nab-paclitaxel and gemcitabine or FOLFIRINOX as first-line treatment in patients with unresectable adenocarcinoma of the pancreas: does sequence matter?. : BMC cancer.

MLA

Vogl Ursula M, Andalibi Haleh, Klaus Alexander, Vormittag Laurenz, Schima Wolfgang, Heinrich Bettina, Kafka Alice, Winkler Thomas and Öhler Leopold. Nab-paclitaxel and gemcitabine or FOLFIRINOX as first-line treatment in patients with unresectable adenocarcinoma of the pancreas: does sequence matter?. : BMC cancer. 20190415.